Loading…
uniQure N.V. is projected to rise to $55.79 by 2027, a +25% move from its current price of $44.48. QURE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $42.08 | $44.49 | $47.03 | +0.02% |
| Jul 13 | $41.13 | $44.49 | $48.13 | +0.03% |
| Jul 14 | $40.42 | $44.50 | $48.99 | +0.05% |
| Jul 15 | $39.83 | $44.51 | $49.73 | +0.06% |
| Jul 16 | $39.32 | $44.51 | $50.40 | +0.08% |
| Jul 17 | $38.86 | $44.52 | $51.01 | +0.09% |
| Jul 18 | $38.45 | $44.53 | $51.57 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.45 | $44.53 | $51.57 | +0.11% |
| Week 2 | $36.22 | $44.58 | $54.87 | +0.22% |
| Week 3 | $34.60 | $44.63 | $57.55 | +0.33% |
| Week 4 | $33.31 | $44.68 | $59.93 | +0.44% |
| Week 5 | $32.21 | $44.73 | $62.11 | +0.55% |
| Week 6 | $31.25 | $44.77 | $64.16 | +0.66% |
| Week 7 | $30.39 | $44.82 | $66.11 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. It offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. It also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering.
uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. (QURE) is a Healthcare asset with a current price of $41.81 and a market cap of $2.87B, ranking 1742.
The 30-day technical picture is bullish, with RSI14 at 60; SMA50 at $29.44 and SMA200 at $28.86. The price has a support level at $24.19 and a resistance level at $49.10, while the 30-day range stretches from $27.63 to $63.26.
The longer-term forecast shows rising averages through 2026–2050, with 2026 avg $41.81, 2030 avg $104.17, and 2050 avg $861.36; ROI figures climb to 149.2% by 2030 and 1960.2% by 2050, reflecting substantial anticipated upside.
A major floor 79.7% below — a decisive break under it would weaken the trend.
The nearest floor, 44.1% below — buyers have tended to step in here.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 41.9% above — clearing it would confirm fresh momentum.
Key QURE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QURE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $42.67 | Buy | $43.24 | Buy |
| MA 10 | $44.13 | Buy | $43.22 | Buy |
| MA 20 | $41.82 | Buy | $40.93 | Buy |
| MA 50 | $31.92 | Buy | $34.03 | Buy |
| MA 100 | $24.49 | Buy | $29.24 | Buy |
| MA 200 | $29.57 | Buy | $26.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.16 | Neutral |
| Stoch RSI (14) | 1.97 | Buy |
| CCI (20) | 9.17 | Neutral |
| Williams %R (14) | -83.59 | Info |
| MACD (12,26,9) | -0.85 | Sell |
| ROC (12) | -13.07 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 16.41 | Buy |
| TRIX (15) | 2.04 | Buy |
| Awesome (5,34) | 7.13 | Buy |
| Ultimate (7,14,28) | 39.06 | Neutral |
| Momentum (10) | -6.47 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 42.84 | Buy |
| ADX (14) | 28.94 | Buy |
| ATR (14) | 1.71 | Info |
The 30-day picture is bullish. RSI14 is 60, with SMA50 at $29.44 and SMA200 at $28.86.
The 30-day range runs from $27.63 to $63.26, indicating notable near-term volatility. Support is identified at $24.19 and resistance at $49.10.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.03 | $44.48 | $67.62 | 0% | Neutral | |
| $40.47 | $55.79 | $83.15 | +25% | Bullish | |
| $42.25 | $61.89 | $98.30 | +39% | Bullish | |
| $51.57 | $79.58 | $132.68 | +79% | Bullish | |
| $76.50 | $123.76 | $214.80 | +178% | Bullish | |
| $85.65 | $144.81 | $260.18 | +226% | Bullish | |
| $87.71 | $154.68 | $286.55 | +248% | Bullish | |
| $88.42 | $162.38 | $309.18 | +265% | Bullish | |
| $86.47 | $165.20 | $322.48 | +271% | Bullish | |
| $101.13 | $200.83 | $401.16 | +352% | Bullish | |
| $149.54 | $332.31 | $729.50 | +647% | Bullish | |
| $443.39 | $985.31 | $2,266.21 | +21.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.03 | $44.48 | $54.73 | +0.00% |
| August 2026 | $38.27 | $46.37 | $58.54 | +4.26% |
| September 2026 | $36.72 | $45.12 | $58.15 | -2.70% |
| October 2026 | $35.52 | $44.19 | $57.94 | -2.07% |
| November 2026 | $37.88 | $47.61 | $63.33 | +7.75% |
| December 2026 | $39.53 | $50.18 | $67.62 | +5.39% |
Click any year to see its month-by-month QURE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The QURE price prediction for 2026 points to an average of $44.48 (low $9.03, high $67.62) — a potential gain of 0% on today's $44.48. Price action looks broadly range-bound.
In 2027, QURE is projected to trade between $40.47 and $83.15, averaging $55.79 — a potential gain of +25% from today's $44.48. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
uniQure N.V.'s 2028 outlook centres on $61.89, within a $42.25 to $98.30 range. That is up +11% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, QURE could reach as high as $132.68, with a base case around $79.58 and support toward $51.57 — roughly +79% from $44.48. Buyers look set to stay in control over this stretch.
Expect QURE to range from $76.50 to $214.80 through 2030. The $123.76 average target implies a +178% move from current prices. That is up +56% on the projected 2029 average. Momentum favours further upside here.
The QURE price prediction for 2031 points to an average of $144.81 (low $85.65, high $260.18) — a potential gain of +226% on today's $44.48. Buyers look set to stay in control over this stretch.
In 2032, QURE is projected to trade between $87.71 and $286.55, averaging $154.68 — a potential gain of +248% from today's $44.48. That is up +7% on the projected 2031 average. Momentum favours further upside here.
uniQure N.V.'s 2033 outlook centres on $162.38, within a $88.42 to $309.18 range. That is up +5% on the projected 2032 average. That marks a +265% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, QURE could reach as high as $322.48, with a base case around $165.20 and support toward $86.47 — roughly +271% from $44.48. Momentum favours further upside here.
Expect QURE to range from $101.13 to $401.16 through 2035. The $200.83 average target implies a +352% move from current prices. That is up +22% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The QURE price prediction for 2040 points to an average of $332.31 (low $149.54, high $729.50) — a potential gain of +647% on today's $44.48. Momentum favours further upside here.
In 2050, QURE is projected to trade between $443.39 and $2,266.21, averaging $985.31 — a potential gain of +21.2x from today's $44.48. That is up +197% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in QURE today (≈ 22.482014 QURE) could be worth
$22,151.71
+$21,151.71 (+2115%) by 2050 · US Dollar
Based on the average projected QURE price of $985.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QUREwould be worth at today's price.
$1,000 invested in QURE on Jul 10, 2025 (≈ 67.204301 QURE) would be worth
$2,989.25
+$1,989.25 (+198.9%) today · 2.99× · US Dollar
Based on a QURE entry price of $14.88 vs. today's $44.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $41.81 | $1,063.86 | +6.4% |
| 1 month ago | $26.82 | $1,658.46 | +65.8% |
| 3 months ago | $15.38 | $2,892.07 | +189.2% |
| 6 months ago | $23.04 | $1,930.56 | +93.1% |
| 1 year ago | $14.88 | $2,989.25 | +198.9% |
| All time (5.0y) ago | $28.21 | $1,576.75 | +57.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QURE forecast.
Our base-case forecast reaches $89.00 around 2030.
Implied market cap at $89.00: $6.12B
The multi-year forecast outlines a strong upward trajectory. By 2030, the average price is projected to be $104.17 with a maximum of $180.94 and a minimum of $64.33, yielding a 149.2% ROI. The 2031–2035 window continues the bullish path, with 2031 avg $135.03 and 2035 avg $178.20; maximums reach $242.78 and $356.14, and ROIs rise to 223% and 326.2% respectively.
In 2040, the average price is forecast at $325.48 with a maximum of $714.77 and a 678.5% ROI. By 2050, the average price could be $861.36 with a maximum of $1,981.13 and a 1960.2% ROI, all while sentiment remains bullish. These are estimates, not guarantees, and are subject to market and clinical development risks.
Tap a question to reveal the answer.
2030 avg $104.17; min $64.33; max $180.94; ROI 149.2%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and high ROI (e.g., 2030 ROI 149.2%, 2050 ROI 1960.2%); these are estimates, not guarantees.
2035 max $356.14; avg $178.20; thus a price above $200 is within the forecast range by 2035.
The current price is $41.81.
RSI14 is 60 with sentiment BULLISH. SMA50 is $29.44 and SMA200 is $28.86. The 30-day range is $27.63 to $63.26, with support at $24.19 and resistance at $49.10.
uniQure N.V. Community Discussion
0Share your uniQure N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.